This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015.

 

Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.

 

The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

 

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:

 

• VEGF
• TNF
• Her2
• CD20
• EGF-R
• B7.1/B7.2 (CD80/CD86)
• IL-6R
• Alpha4/beta1/7 integrin
• IgE
• RSV
• RANKL
• Complement C5
• IL-12/IL-23
• CD52

 

 

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

• Anti-TNF Antibody Sales 2014
• Cancer Antibody Sales 2014
• Other Anti-Inflammatory Antibody Sales 2014
• Ophthalmic Antibody Sales 2014
• Cardiometabolic & Antiviral Antibody Sales 2014

• Avastin Sales & Pipeline
• Zaltrap Sales & Pipeline
• Cyramza Sales & Pipeline

• Anti-VEGF & Antibody Combination Pipeline
• Bispecific Anti-VEGF Antibody Pipeline

• Anti-VEGF-R & Antibody Combination Pipeline
• Bispecific Anti-VEGF-R Antibody Pipeline

• Lucentis Sales & Pipeline
• Eylea Sales & Pipeline

• Anti-VEGF Pipeline in Ophthalmology
• Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology

Lucentis Biosimilar Pipeline

 

Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets

Tab. 2: Additional indications of branded anti-TNF antibodies under development 

Tab. 3: 2014 Sales of anti-TNF Antibodies

Marketed TNF Antibodies

Humira Sales & Pipeline

Remicade Sales & Pipeline

Enbrel Sales & Pipeline

Simponi Sales & Pipeline

Cimzia Sales & Pipeline

Biosuperior / Biobetter TNF Antibodies

Biosimilar TNF Antibodies

Humira Biosimilar Antibody Pipeline

Remicade Biosimilar Antibody Pipeline

Enbrel Biosimilar Antibody Pipeline

Cimzia Biosimilar Antibody Pipeline

 

Marketed Her2 Antibodies

Herceptin Sales & Pipeline

Perjeta Sales & Pipeline

Kadcyla Sales & Pipeline

Trastuzumab Biosuperiors

Engineered Her2 Antibodies

Bi- and Multispecific Her2 Antibodies

Her2 Antibody-Drug Conjugates

Other Her2 Antibodies

Herceptin Biosimilars

 

5) CD20 Antibodies 

2014 Sales of CD20 Antibodies

Marketed CD20 Antibodies & Sales

Rituxan/MabThera Pipeline & Sales

Gazyva/ Gazyvaro Pipeline & Sales

Arzerra Pipeline & Sales

Zevalin Pipeline & Sales

Biosuperior CD20 Antibodies

Biosimilar CD20 Antibodies

Rituxan/MabThera (rituximab) Biosimilars

 

2014 Sales of EGF-R Antibodies

Marketed EGF-R Antibodies

Erbitux Sales & Pipeline

Vectibix Sales & Pipeline

Nimotuzumab Pipeline

EGF-R Antibody Biosuperiors

Engineered EGF-R Antibodies

Bi- and Multispecific EGF-R Antibodies

EGF-R Antibody-Drug Conjugates

EGF-R Antibody Biosimilars

Cetuximab Biosimilars

 

Marketed RANKL Antibodies

Prolia Sales & Pipeline

XGEVA Sales & Pipeline

Ranmark/Pralia Pipeline

Biosuperior RANKL Antibodies

Biosimilar RANKL Antibodies

 

Marketed C5 Antibody Sales & Pipeline

Biosuperior C5 Antibodies

Biosimilar C5 Antibodies

 

Marketed IL-12/-23 Antibody Sales & Pipeline

 

Marketed alpha4/beta1/7 Antibody Sales & Pipeline

 

Marketed IgE Antibody Sales & Pipeline

Biosuperior IgE Antibodies

Biosimilar IgE Antibodies

 

Marketed CD80/86 Antibodies Sales & Pipeline

Biosuperior CD80/86 Antibodies

Biosimilar CD80/86 Antibodies

 

Marketed IL-6R Antibody Sales & Pipeline

Biosuperior IL-6R Antibodies

Biosimilar IL-6R Antibodies

Marketed RSV Antibody Sales

Biosuperior RSV Antibodies

Biosimilar RSV Antibodies

 

Marketed CD52 Antibody Sales 

Biosuperor CD52 Antibodies

Biosimilar CD52 Antibodies